DOCSLIB.ORG

Base Excision Repair Defects Invoke Hypersensitivity to PARP Inhibition

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Base Excision Repair Defects Invoke Hypersensitivity to PARP Inhibition Published OnlineFirst April 25, 2014; DOI: 10.1158/1541-7786.MCR-13-0502 Molecular Cancer DNA Damage and Repair Research Base Excision Repair Defects Invoke Hypersensitivity to PARP Inhibition Julie K. Horton, Donna F. Stefanick, Rajendra Prasad, Natalie R. Gassman, Padmini S. Kedar, and Samuel H. Wilson Abstract PARP-1 is important for the recognition of both endogenous and exogenous DNA damage, and binds to DNA strand breaks including intermediates of base excision repair (BER). Once DNA-bound, PARP-1 becomes catalytically activated synthesizing PAR polymers onto itself and other repair factors (PARylation). As a result, BER repair proteins such as XRCC1 and DNA polymerase b (pol b) are more efficiently and rapidly recruited to sites of DNA damage. In the presence of an inhibitor of PARP activity (PARPi), PARP-1 binds to sites of DNA damage, but PARylation is prevented. BER enzyme recruitment is hindered, but binding of PARP-1 to DNA is stabilized, À À À À impeding DNA repair and leading to double-strand DNA breaks (DSB). Deficiencies in pol b / and Xrcc1 / cells resulted in hypersensitivity to the PARP inhibitor 4-AN and reexpression of pol b or XRCC1, in these contexts, reversed the 4-AN hypersensitivity phenotype. BER deficiencies also showed evidence of replication defects that lead to DSB-induced apoptosis upon PARPi treatment. Finally, the clinically relevant PARP inhibitors olaparib and À À À À veliparib also exhibited hypersensitivity in both pol b / and Xrcc1 / BER-deficient cells. These results reveal heightened sensitivity to PARPi as a function of BER deficiency. Implications: BER deficiency represents a new therapeutic opportunity to enhance PARPi efficacy. Visual Overview: http://mcr.aacrjournals.org/content/12/8/1128/F1.large.jpg. Mol Cancer Res; 12(8); 1128–39. Ó2014 AACR. Introduction as a scaffold able to modulate and coordinate the various steps of BER. In this repair pathway, base lesions removed by The base excision repair (BER) pathway is a primary fi mechanism for repair of endogenous and exogenous base a lesion-speci c monofunctional glycosylase produce abasic lesions in DNA. PARP-1, the first discovered member of the sites that are cleaved by AP endonuclease 1. This results in a repair intermediate with a gap containing a 30-OH and 50- PARP family and an abundant nuclear protein, is particu- fl larly important for DNA damage recognition involving deoxyribose phosphate (dRP) ap at the margins. DNA pol b removes the 50-dRP flap through its lyase activity, and binding to strand breaks in DNA (1), including intermedi- fi ates of BER (2). Once bound to damaged DNA, PARP-1 conducts gap- lling DNA synthesis leaving a nicked DNA that is a substrate for DNA ligase. Both XRCC1-deficient becomes catalytically activated synthesizing PAR polymers – fi fi attached to itself and other repair factors (PARylation). As a and pol b de cient mouse broblasts are hypersensitive to the DNA base methylating agent methyl methanesulfonate result of PARP-1 auto-PARylation, BER proteins such as fi DNA polymerase b (pol b) and the XRCC1-DNA ligase (MMS), and this is linked to a repair de ciency as measured IIIa (lig-IIIa) complex are recruited more efficiently to sites by accumulation of strand breaks (3). of DNA damage. In the presence of an inhibitor of PARP catalytic activity XRCC1 is a multidomain protein with no known catalytic (PARPi), PARP-1 binds at sites of DNA damage, but auto- activity. Yet, it interacts with a number of repair proteins, PARylation is prevented. In the absence of PAR polymers, e.g., PARP-1, pol b, and lig-IIIa, and is thought to function BER enzyme recruitment is hindered, but binding of PARP- 1 to DNA is stabilized, impeding DNA repair (4). PARPi- treated wild-type cells are highly sensitive to MMS, whereas Parp-1À/À Authors' Affiliation: Laboratory of Structural Biology, NIEHS, NIH, cells demonstrate only moderate MMS hyper- Research Triangle Park, North Carolina sensitivity (5). Thus, the cellular cytotoxicity phenotype Note: Supplementary data for this article are available at Molecular Cancer associated with inhibition of the PARP-1 enzyme is not Research Online (http://mcr.aacrjournals.org/). equivalent to PARP-1 deletion (4, 5). Previous results Corresponding Author: Samuel H. Wilson, NIH, 111 T.W. Alexander Drive, suggested that the DNA-bound and inhibited PARP-1 Research Triangle Park, NC 27709. Phone: 919-541-4701; Fax: 919-541- protein is cytotoxic as a function of formation of replica- 4724; E-mail: [email protected] tion-dependent double-strand breaks (DSB; ref. 6). This doi: 10.1158/1541-7786.MCR-13-0502 type of DSB is preferentially repaired by the homologous Ó2014 American Association for Cancer Research. recombination (HR) pathway. 1128 Mol Cancer Res; 12(8) August 2014 Downloaded from mcr.aacrjournals.org on September 27, 2021. © 2014 American Association for Cancer Research. Published OnlineFirst April 25, 2014; DOI: 10.1158/1541-7786.MCR-13-0502 BER Deficiency and Hypersensitivity to PARPi BRCA1 and BRCA2 are components of the HR path- ascertained by Western blotting. Independently derived way, and BRCA1/2-deficient cells were shown to be SV40-transformed wild-type and pol b null cells (36.3 and hypersensitive to treatment with a PARPi (7, 8). This key 38D4) have also been described (16). Stable transfection of combination became known as a form of "synthetic 38D4 pol b null cells with wild-type pol b and its 8-kDa dRP lethality" where there is synergy between two otherwise lyase domain and selection in G418 (600 mg/mL) or puro- nonlethal events, here a PARPi resulting in DSB formation mycin (6 mg/mL), respectively, have been outlined (16). fi and a genetic de ciency resulting in loss of the pathway Cells were routinely grown at 34 C in a 10% CO2 incubator required for DSB repair. A recent model predicts that in high glucose DMEM supplemented with 10% FBS inactivation of both PARP-1 and BRCA activities at the (HyClone), glutaMAX 1, and 80 mg/mL hygromycin same time would result in repair through an error-prone (Invitrogen). þ þ À À nonhomologous end-joining mechanism (9). Because car- Xrcc1 / and Xrcc1 / p53-deficient mouse embryonic riers of germ-line heterozygous BRCA mutations are pre- fibroblasts were obtained from Dr. Robert Tebbs (17). disposed to cancer after loss of the wild-type allele, PARPi These cells were maintained in low-glucose DMEM (Invi- were rapidly considered for targeted monotherapy that trogen) supplemented with 10% FBS at 37C. A clone should not affect other repair-competent cells (10). containing the full-length open reading frame of mouse Screening for determinants of PARPi sensitivity has become XRCC1 (Invitrogen) was subcloned into the pDONR221 critical (11, 12). A high throughput siRNA screen targeting vector and then the pEF-DEST51 vector utilizing Gateway À À 98% of known DNA repair proteins implicated several HR technology (Invitrogen). Xrcc1 / cells were stably trans- proteins, but additionally identified XRCC1, involved in BER fected with the full-length wild-type XRCC1 construct (11). The most striking PARPi-induced enhancement of (WT17 cells). Other stable cell lines with mutant XRCC1 cytotoxicity in mouse cell lines is observed with alkylating proteins have been engineered. V88R XRCC1-transfected agents resulting in damage repaired by a specificBERsubpath- cells (XV2 cells) are known to have interrupted binding to way involving pol b and XRCC1 (13). With MMS and PARPi pol b (14, 18, 19). Reduced C12A XRCC1 protein trans- combination treatment in mouse fibroblasts, the effects of fectants (XRE8 cells), unable to form the C12-C20 disulfide PARPi and BER deficiency are clearly not epistatic, but instead bond and also deficient in interaction with pol b (20), have are additive (5, 14). Thus, PARPi does not target the BER been characterized previously (14). Another XRCC1 deficiency mediators studied, pol b and XRCC1, but instead mutant, L360R, was introduced by site-directed mutagen- works through a separate mechanism. esis of the pDONR221 vector and subcloned into pEF- Sensitization to MMS is consistent with increased PARP DEST51. The resulting vector, pXL, was sequence verified. binding sites in DNA in the absence of efficient BER. Transfection was conducted as described, clones were select- However, the question of PARPi hypersensitivity as a ed with blasticidin (10 mg/mL; Invitrogen), and XRCC1 function of BER deficiency has not been widely studied. expression was confirmed by Western blotting. Mycoplasma Because the BER deficiencies mediated by pol b and XRCC1 testing was performed routinely on all cell lines using a knockouts are additive with combination treatment, we MycoAlert Mycoplasma detection kit (Lonza). proposed that cells deficient in these BER factors would be hypersensitive to treatment with a PARPi. We suspected that Determination of total cellular PAR endogenous DNA damage would effectively substitute for Cellular PAR levels were quantified using the PARP in the alkylating agent used in combination treatment. Here, vivo Pharmacodynamic Assay 2nd Generation (PDA II) we determined whether BER deficiency can lead to hyper- Kit (4520-096-K; Trevigen) as described previously (21). sensitivity to 4-amino-1,8-naphthalimde (4-AN), a com- Cells were seeded in 60-mm dishes at 106 cells per dish mercially available PARPi. Results were compared with and analyzed the following day. Dishes were placed on ice those obtained with clinically used PARPi olaparib and and lysed according to the kit protocol. Cell counts were veliparib. We find that BER deficiency as a result of either verified to ensure no growth differential between cell lines. pol b deletion or XRCC1 deletion is associated with PARPi After cell lysis and DNA digestion, total protein amounts À À hypersensitivity. These results suggest that BER deficiency were determined for each sample, and 4 mgofpol b / and À À þ þ þ þ could represent a therapeutic opportunity for single-agent Xrcc1 / cell extracts and 10 mgofpol b / and Xrcc1 / PARPi therapy.
Load more

Recommended publications
  • Differential Effects of the Poly (ADP-Ribose)Polymerase (PARP
    British Journal of Cancer (2001) 84(1), 106–112 © 2001 Cancer Research Campaign doi: 10.1054/ bjoc.2000.1555, available online at http://www.idealibrary.com on http://www.bjcancer.com Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro KJ Bowman*, DR Newell, AH Calvert and NJ Curtin Cancer Research Unit, University of Newcastle upon Tyne Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, UK Summary The potent novel poly(ADP-ribose) polymerase (PARP) inhibitor, NU1025, enhances the cytotoxicity of DNA-methylating agents and ionizing radiation by inhibiting DNA repair. We report here an investigation of the role of PARP in the cellular responses to inhibitors of topoisomerase I and II using NU1025. The cytotoxicity of the topoisomerase I inhibitor, camptothecin, was increased 2.6-fold in L1210 cells by co-incubation with NU1025. Camptothecin-induced DNA strand breaks were also increased 2.5-fold by NU1025 and exposure to camptothecin-activated PARP. In contrast, NU1025 did not increase the DNA strand breakage or cytotoxicity caused by the topoisomerase II inhibitor etoposide. Exposure to etoposide did not activate PARP even at concentrations that caused significant levels of apoptosis. Taken together, these data suggest that potentiation of camptothecin cytotoxicity by NU1025 is a direct result of increased DNA strand breakage, and that activation of PARP by camptothecin-induced DNA damage contributes to its repair and consequently cell survival. However, in L1210 cells at least, it would appear that PARP is not involved in the cellular response to etoposide-mediated DNA damage.
    [Show full text]
  • Protein Kinase CK2 in DNA Damage and Repair
    Review Article Protein kinase CK2 in DNA damage and repair Mathias Montenarh Medical Biochemistry and Molecular Biology, Saarland University, Homburg, Germany Correspondence to: Mathias Montenarh. Medical Biochemistry and Molecular Biology, Saarland University, Building 44, D-66424 Homburg, Germany. Email: [email protected]. Abstract: Protein kinase CK2, formerly known as casein kinase 2, is a ubiquitously expressed serine/ threonine kinase, which is absolutely required for cell viability of eukaryotic cells. The kinase occurs predominantly as a tetrameric holoenzyme composed of two regulatory α or α' subunits and two non- catalytic β subunits. It is highly expressed and highly active in many tumour cells. The proliferation promoting as well as the anti-apoptotic functions have made CK2 an interesting target for cancer therapy. It phosphorylates numerous substrates in eukaryotic cells thereby regulating a variety of different cellular processes or signalling pathways. Here, I describe the role of CK2 in DNA damage recognition followed by cell cycle regulation and DNA repair. It turns out that CK2 phosphorylates a number of different proteins thereby regulating their enzymatic activity or platform proteins which are required for recruiting proteins for DNA repair. In addition, the individual subunits bind to various proteins, which may help to target the kinase to places of DNA damage and repair. Recently developed pharmacological inhibitors of the kinase activity are potent regulators of the CK2 activity in DNA repair processes. Since DNA damaging agents are used in cancer therapy the knowledge of CK2 functions in DNA repair as well as the use of specific inhibitors of CK2 may improve cancer treatment in the future.
    [Show full text]
  • Base Excision Repair Synthesis of DNA Containing 8-Oxoguanine in Escherichia Coli
    EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 35, No. 2, 106-112, April 2003 Base excision repair synthesis of DNA containing 8-oxoguanine in Escherichia coli Yun-Song Lee1,3 and Myung-Hee Chung2 Introduction 1Division of Pharmacology 8-oxo-7,8-dihydroguanine (8-oxo-G) in DNA is a muta- Department of Molecular and Cellular Biology genic adduct formed by reactive oxygen species Sungkyunkwan University School of Medicine (Kasai and Nishimura, 1984). As a structural prefe- Suwon 440-746, Korea rence, adenine is frequently incorporated into oppo- 2Department of Pharmacology site template 8-oxo-G (Shibutani et al., 1991), and 8- Seoul National University College of Medicine oxo-dGTP is incorporated into opposite template dA Jongno-gu, Seoul 110-799, Korea during DNA synthesis (Cheng et al., 1992). Thus, un- 3Corresponding author: Tel, 82-31-299-6190; repaired, these mismatches lead to GT and AC trans- Fax, 82-31-299-6209; E-mail, [email protected] versions, respectively (Grollman and Morya, 1993). In Escherichia coli, several DNA repair enzymes, Accepted 29 March 2003 preventing mutagenesis by 8-oxo-G, are known as the GO system (Michaels et al., 1992). The GO system Abbreviations: 8-oxo-G, 8-oxo-7,8-dihydroguanine; Fapy, 2,6-dihy- consists of MutT (8-oxo-dGTPase), MutM (2,6-dihydro- droxy-5N-formamidopyrimidine; FPG, Fapy-DNA glycosylase; BER, xy-5N-formamidopyrimidine (Fapy)-DNA glycosylase, base excision repair; AP, apurinic/apyrimidinic; dRPase, deoxyribo- Fpg) and MutY (adenine-DNA glycosylase). 8-oxo- phosphatase GTPase prevents incorporation of 8-oxo-dGTP into DNA by degrading 8-oxo-dGTP.
    [Show full text]
  • Association of the XRCC1 Gene Polymorphisms with Cancer Risk in Turkish Breast Cancer Patients
    EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 36, No. 6, 572-575, December 2004 Association of the XRCC1 gene polymorphisms with cancer risk in Turkish breast cancer patients Ugur Deligezer1 and Nejat Dalay1,2 and family history (Madigan et al., 1995). In the majority of cases the cause of the disease is still 1Department of Basic Oncology obscure. Amino acid substitutions in the DNA repair Oncology Institute Istanbul University genes as result of genetic polymorphisms may lead Istanbul, Turkey to alterations in DNA repair capacity and affect the 2Corresponding author: Tel, 90-212-5313100; susceptibility to cancer. Polymorphic alleles have Fax, 90-212-5348078; E-mail, [email protected] been described for many DNA repair genes including the genes responsible for nucleotide and base Accepted 9 December 2004 excision repair (Shen et al., 1998; Fan et al., 1999). Recent data suggest that DNA repair capacity may Abbreviations: BRCA1, Breast cancer-associated gene 1; BRCT-1, vary between individuals (Berwick, 2000) and is lower BRCA1 C terminus repeat 1; CI, Confidence interval; OR, Odds in cancer patients than healthy controls (Mohrenweiser ratio; XRCC1, X-ray repair cross-complementing group 1 and Jones, 1998). It has been hypothesized that multiple alleles may act in combination in conferring cancer risk (Mohrenweiser and Jones, 1998; Shen et al., 1998). Abstract The protein encoded by the XRCC1 gene plays an important role in base excision repair and removes The X-ray repair cross-complementing group 1 base adducts formed by ionizing radiation and alk- (XRCC1) gene is believed to play an important role ylating agents (Yu et al., 1999).
    [Show full text]
  • XRCC3 Gene Polymorphism Is Associated with Survival in Japanese Lung Cancer Patients
    Int. J. Mol. Sci. 2012, 13, 16658-16667; doi:10.3390/ijms131216658 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Article XRCC3 Gene Polymorphism Is Associated with Survival in Japanese Lung Cancer Patients Kayo Osawa 1,*, Chiaki Nakarai 1, Kazuya Uchino 2, Masahiro Yoshimura 2, Noriaki Tsubota 3, Juro Takahashi 1 and Yoshiaki Kido 1,4 1 Faculty of Health Sciences, Kobe University Graduate School of Health Sciences, Kobe 654-0142, Japan; E-Mails: [email protected] (C.N.); [email protected] (J.T.); [email protected] (Y.K.) 2 Department of General Thoracic Surgery, Hyogo Cancer Center, Akashi 673-0021, Japan; E-Mails: [email protected] (K.U.); myoshi@ hp.pref.hyogo.jp (M.Y.) 3 Department of Thoracic Oncology, Hyogo College of Medicine, Nishinomiya 663-8501, Japan; E-Mail: [email protected] 4 Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +81-78-796-4581; Fax: +81-78-796-4509. Received: 28 September 2012; in revised form: 7 November 2012 / Accepted: 28 November 2012 / Published: 5 December 2012 Abstract: We focused on OGG1 Ser326Cys, MUTYH Gln324His, APEX1 Asp148Glu, XRCC1 Arg399Gln, and XRCC3 Thr241Met and examined the relationship between the different genotypes and survival of Japanese lung cancer patients. A total of 99 Japanese lung cancer patients were recruited into our study. Clinical data were collected, and genotypes of the target genes were identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
    [Show full text]
  • Aprataxin Localizes to Mitochondria and Preserves Mitochondrial Function
    Aprataxin localizes to mitochondria and preserves mitochondrial function Peter Sykora, Deborah L. Croteau, Vilhelm A. Bohr1, and David M. Wilson III1,2 Laboratory of Molecular Gerontology, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224 Edited* by James E. Cleaver, University of California, San Francisco, CA, and approved March 23, 2011 (received for review January 4, 2011) Ataxia with oculomotor apraxia 1 is caused by mutation in the APTX and flap endonuclease 1 (FEN1), has confirmed that BER in the gene, which encodes the DNA strand-break repair protein apra- mitochondria has many, if not all, proteins and pathways active in taxin. Aprataxin exhibits homology to the histidine triad superfam- nuclear BER (26–29). These facts led us to speculate that apra- ily of nucleotide hydrolases and transferases and removes 5′- taxin might have a significant role in the maintenance of mtDNA. adenylate groups from DNA that arise from aborted ligation reac- This hypothesis is also supported by similarities between AOA1 tions. We report herein that aprataxin localizes to mitochondria and diseases associated with mitochondrial dysfunction, such as in human cells and we identify an N-terminal amino acid sequence FA (30). Like AOA1, FA patients are not susceptible to cancer that targets certain isoforms of the protein to this intracellular but frequently present with peripheral neuropathy and pro- compartment. We also show that transcripts encoding this unique gressive ataxia. FA and AOA1 patients are also reported to be fi N-terminal stretch are expressed in the human brain, with highest de cient in coenzyme Q10, an essential component of the elec- tron transport chain and potent antioxidant within the mito- production in the cerebellum.
    [Show full text]
  • XRCC1 Mutation Is Associated with PARP1 Hyperactivation and Cerebellar Ataxia
    XRCC1 mutation is associated with PARP1 hyperactivation and cerebellar ataxia Article (Accepted Version) Hoch, Nicolas C, Hanzlikova, Hana, Rulten, Stuart L, Tétreault, Martine, Komulainen, Emilia, Ju, Limei, Hornyak, Peter, Zeng, Zhihong, Gittens, William, Rey, Stephanie A, Staras, Kevin, Mancini, Grazia M S, McKinnon, Peter J, Wang, Zhao-Qi, Wagner, Justin D et al. (2017) XRCC1 mutation is associated with PARP1 hyperactivation and cerebellar ataxia. Nature, 541. pp. 87-91. ISSN 0028-0836 This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/66490/ This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher’s version. Please see the URL above for details on accessing the published version. Copyright and reuse: Sussex Research Online is a digital repository of the research output of the University. Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available. Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.
    [Show full text]
  • Variations in HSPA1B at 6P21.3 Are Associated with Lung Cancer Risk And
    Author Manuscript Published OnlineFirst on October 28, 2011; DOI: 10.1158/0008-5472.CAN-11-1409 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Variations in HSPA1B at 6p21.3 are Associated with Lung Cancer Risk and Prognosis in Chinese Populations Huan Guo1, Qifei Deng1, Chen Wu2, Lingmin Hu3, Sheng Wei1, Ping Xu4, Dan Kuang1, Li Liu5, Zhibin Hu3, Xiaoping Miao2, Hongbing Shen3, Dongxin Lin2, and Tangchun Wu1 Authors' Affiliations: 1Institute of Occupational Medicine and Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; 2Department of Etiology and Carcinogenesis, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; 3Department of Epidemiology and Biostatistics, Cancer Center of Nanjing Medical University, Nanjing, China; 4Department of Oncology, Wuhan Iron and Steel (Group) Corporation Staff-Worker Hospital, Wuhan, China; and 5Cancer Center, Union Hospital, Huazhong University of Science and Technology, Wuhan, China. Corresponding Author: Tangchun Wu, Institute of Occupational Medicine, School of Public Health, Tongji Medical College, HUST, 13 Hangkong Rd, Wuhan 430030, Hubei, China. Phone: +86-27-83692347; Fax: +86-27-83692560; E-mail: [email protected]. Grant Support This study is supported by the National Basic Research Program grant 2011CB503800, the National High Technology Project grant 2009AA022705, and the Downloaded from cancerres.aacrjournals.org on September 26, 2021. © 2011 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 28, 2011; DOI: 10.1158/0008-5472.CAN-11-1409 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • Alternative Okazaki Fragment Ligation Pathway by DNA Ligase III
    Genes 2015, 6, 385-398; doi:10.3390/genes6020385 OPEN ACCESS genes ISSN 2073-4425 www.mdpi.com/journal/genes Review Alternative Okazaki Fragment Ligation Pathway by DNA Ligase III Hiroshi Arakawa 1,* and George Iliakis 2 1 IFOM-FIRC Institute of Molecular Oncology Foundation, IFOM-IEO Campus, Via Adamello 16, Milano 20139, Italy 2 Institute of Medical Radiation Biology, University of Duisburg-Essen Medical School, Essen 45122, Germany; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +39-2-574303306; Fax: +39-2-574303231. Academic Editor: Peter Frank Received: 31 March 2015 / Accepted: 18 June 2015 / Published: 23 June 2015 Abstract: Higher eukaryotes have three types of DNA ligases: DNA ligase 1 (Lig1), DNA ligase 3 (Lig3) and DNA ligase 4 (Lig4). While Lig1 and Lig4 are present in all eukaryotes from yeast to human, Lig3 appears sporadically in evolution and is uniformly present only in vertebrates. In the classical, textbook view, Lig1 catalyzes Okazaki-fragment ligation at the DNA replication fork and the ligation steps of long-patch base-excision repair (BER), homologous recombination repair (HRR) and nucleotide excision repair (NER). Lig4 is responsible for DNA ligation at DNA double strand breaks (DSBs) by the classical, DNA-PKcs-dependent pathway of non-homologous end joining (C-NHEJ). Lig3 is implicated in a short-patch base excision repair (BER) pathway, in single strand break repair in the nucleus, and in all ligation requirements of the DNA metabolism in mitochondria. In this scenario, Lig1 and Lig4 feature as the major DNA ligases serving the most essential ligation needs of the cell, while Lig3 serves in the cell nucleus only minor repair roles.
    [Show full text]
  • Poly(ADP-Ribose) Polymerase-1 Hyperactivity at DNA Single-Strand Breaks Triggers Seizures and Shortened Lifespan
    bioRxiv preprint doi: https://doi.org/10.1101/431916; this version posted October 1, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Poly(ADP-ribose) Polymerase-1 Hyperactivity at DNA Single-Strand Breaks Triggers Seizures and Shortened Lifespan Emilia Komulainen1, Stephanie Rey2, Stuart Rulten1, Limei Ju1, Peter J. McKinnon3, Kevin Staras2, and Keith W Caldecott1 1Genome Damage and Stability Centre, School oF LiFe Sciences, University oF Sussex, Falmer, Brighton, BN1 9RQ 2Sussex Neuroscience, School oF LiFe Sciences, University oF Sussex, Falmer, Brighton, BN1 9QG 3Dept. Genetics, St Jude Children’s Research Hospital, Memphis, Tennessee, USA 38105 To whom correspondence should be addressed; [email protected] or [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/431916; this version posted October 1, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Defects in DNA strand break repair can trigger seizures that are often intractable and life-threatening. However, the molecular mechanism/s by which unrepaired DNA breaks trigger seizures are unknown. Here, we show that hyperactivity of the DNA break sensor protein poly(ADP-ribose) polymerase-1 is widespread in DNA single-strand break repair defective XRCC1-mutant mouse brain, including the hippocampus and cortex.
    [Show full text]
  • Oxidation State of the XRCC1 N-Terminal Domain Regulates DNA Polymerase Β Binding Affinity
    Oxidation state of the XRCC1 N-terminal domain regulates DNA polymerase β binding affinity Matthew J. Cuneo and Robert E. London1 Laboratory of Structural Biology, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709 Edited by Lorena S. Beese, Duke University Medical Center, Durham, NC, and approved March 2, 2010 (received for review December 7, 2009) Formation of a complex between the XRCC1 N-terminal domain identify a direct, redox-dependent pathway for modulating the (NTD) and DNA polymerase β (Pol β) is central to base excision re- activity of XRCC1 and, in turn, the DNA repair process. pair of damaged DNA. Two crystal forms of XRCC1-NTD complexed with Pol β have been solved, revealing that the XRCC1-NTD is able Results to adopt a redox-dependent alternate fold, characterized by a Analysis by Small-Angle X-Ray Scattering. We initially focused on the disulfide bond, and substantial variations of secondary structure, characterization of the complex formed between the XRCC1- folding topology, and electrostatic surface. Although most of NTD and the Pol β catalytic domain (Pol β CD), because it these structural changes occur distal to the interface, the oxidized appears that the N-terminal Pol β lyase domain does not parti- XRCC1-NTD forms additional interactions with Pol β, enhancing af- cipate in this interaction, and because the position of this domain finity by an order of magnitude. Transient disulfide bond formation can be variable in the absence of a gapped DNA substrate (12). is increasingly recognized as an important molecular regulatory The interaction of XRCC1-NTD with the Pol β CD was first in- mechanism.
    [Show full text]
  • Defective Base Excision Repair in the Response to DNA Damaging Agents in Triple
    bioRxiv preprint doi: https://doi.org/10.1101/685271; this version posted June 27, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Defective base excision repair in the response to DNA damaging agents in triple 2 negative breast cancer 3 4 Kevin J. Lee1, Cortt G. Piett2, Joel F Andrews1, Elise Mann3, Zachary D. Nagel2, and 5 Natalie R. Gassman1,3* 6 7 1Mitchell Cancer Institute, University of South Alabama, 1660 Springhill Avenue, Mobile, 8 AL 36604, USA 9 2Harvard T.H. Chan School of Public Health, Harvard University, 220 Longwood 10 Avenue, Boston, MA 02115, USA 11 3University of South Alabama College of Medicine, 307 N University Blvd, Mobile, AL 12 36688 13 *Corresponding author: [email protected] 14 15 Running title: Defective BER in triple negative breast cancer 16 17 Funding: This work was supported by R21ES028015 from National Institutes of Health, 18 National Institute of Environmental Health Sciences. The authors declare there are not 19 conflicts of interest. Editorial support was provided by the Dean’s Office, University of 20 South Alabama College of Medicine. 21 Competing interests statement: The authors declare there are no conflicts of interest. 22 1 bioRxiv preprint doi: https://doi.org/10.1101/685271; this version posted June 27, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 23 Abstract 24 DNA repair defects have been increasingly focused on as therapeutic targets.
    [Show full text]